The pharmacokinetics of fluconazole (50 mg, single oral dose) in saliva and plasma were determined for five healthy subjects and five patients who underwent radiotherapy (dose, >45 Gy over a 6-week period) in the salivary gland area and suffered from oropharyngeal candidiasis. Saliva was collected after electrical stimulation. Fluconazole was measured by liquid chromatography. From healthy volunteers and patients, saliva and plasma were sampled from 0 to 24 h. Although fluconazole penetration kinetics were significantly slowed down in irradiated patients, saliva concentrations of fluconazole were higher than those in the plasma, except at 1 h. In the postdistribution phase, the saliva/plasma concentration ratio was in the range of 1.2 to 1.4, and there was no significant difference between healthy subjects and patients. The saliva concentration of fluconazole was over 1 mg/liter throughout the entire interval 2 to 24 h after drug intake. From these results, the clinical efficacy of fluconazole for oropharyngeal candidiasis is not expected to be less than that in subjects with normal salivary glands, provided that salivary secretion remains.Fluconazole is a broad-spectrum antifungal agent approved in several countries for the treatment of some superficial and deep mycoses. Comparative trials have shown fluconazole to be equal or superior to ketoconazole in the treatment of oropharyngeal candidiasis in patients with AIDS (7) or cancer (17). Fluconazole exhibits a high penetration into body tissues as demonstrated recently by positron emission tomography (9). The volume of distribution of fluconazole approximates that of total body water, the drug exhibits a low level of protein binding (12%) to plasma proteins, and concentrations in saliva, sputum, and vaginal and blister fluid equal those measured in plasma (4). Fluconazole also penetrates into the central nervous system, with levels in the cerebrospinal fluid between 50 and 90% of corresponding levels in plasma, even in the absence of meningitis (11). However, physiological or pathological events can affect tissue penetration and thus possibly clinical outcome. Among these events, irradiation of the salivary glands at a dose greater than 45 Gy results in stomatitis, opportunistic infections (especially candidiasis), increased viscosity of saliva, and qualitative and quantitative modifications of its composition (14,20,22). These modifications are able to decrease penetration of drugs into the salivary gland (13, 18). Although there is no clear relation between fluconazole levels in saliva and clinical outcome, very low levels in saliva or absence of saliva caused by irradiation would be a priori detrimental to efficacy. Indeed, the only clinical failure in the study by Dupont and Drouhet (8) was in an irradiated patient who had no salivary secretion. Thus, the pharmacokinetic parameters describing fluconazole assimilation into saliva were determined for a population of patients who underwent radiotherapy in the salivary gland area.* Corresponding author.
MATERIA...